Regeneron Pharmaceuticals
REGN
447 hedge funds and large institutions have $21.3B invested in Regeneron Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 155 increasing their positions, 181 reducing their positions, and 47 closing their positions.
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
2% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 47
5% less capital invested
Capital invested by funds: $22.3B → $21.3B (-$1.02B)
1% less funds holding
Funds holding: 452 → 447 (-5)
14% less repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 181
38% less call options, than puts
Call options by funds: $279M | Put options by funds: $448M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$567M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$353M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
+$265M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$193M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$106M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$388M |
| 2 |
CCI
Columbus Circle Investors
|
-$138M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$137M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$98.7M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$83.9M |
REGN Hedge Fund Activity: Q2 2014 in Review
447 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2014, worth a combined $21.3B — down 4.6% from $22.3B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of REGN and 46 opened new positions — a net loss of 1 holder — while 181 trimmed existing stakes and 155 added.
The largest buyer was Viking Global Investors, adding an estimated $567M. The largest seller was T. Rowe Price Associates, cutting an estimated $388M.
- 447 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2014, down from 452 in Q1 2014.
- Funds reported $21.3B of Regeneron Pharmaceuticals stock for Q2 2014, down 4.6% quarter-over-quarter.
- 46 funds opened new Regeneron Pharmaceuticals positions in Q2 2014 and 47 closed out, a net change of -1 holder.
- The largest Regeneron Pharmaceuticals buyer in Q2 2014 was Viking Global Investors, an estimated $567M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $388M sold.
Based on aggregated 13F filings for Q2 2014.